Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Trends in Molecular Medicine|April 27, 2017
TREM2, Microglia, and Neurodegenerative DiseasesFelix L Yeh, David V Hansen, Morgan ShengBiophysical Journal|July 8, 2009
Biophysical characterization of styryl dye-membrane interactionsYao Wu, Felix L Yeh, Fei Mao, et al.Neuron|August 2, 2016
TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by MicrogliaFelix L Yeh, Yuanyuan Wang, Irene Tom, et al.Biochemistry|November 4, 2011
Retargeted clostridial neurotoxins as novel agents for treating chronic diseasesFelix L Yeh, Yiming Zhu, William H Tepp, et al.The Journal of Cell Biology|August 8, 2012
All three components of the neuronal SNARE complex contribute to secretory vesicle dockingYao Wu, Yiwen Gu, Mary K Morphew, et al.Plos Pathogens|December 3, 2010
SV2 mediates entry of tetanus neurotoxin into central neuronsFelix L Yeh, Min Dong, Jun Yao, et al.Cell Reports|August 9, 2016
Interneuronal Transfer and Distal Action of Tetanus Toxin and Botulinum Neurotoxins A and D in Central NeuronsEwa Bomba-Warczak, Jason D Vevea, Joel M Brittain, et al.Cell Reports|June 1, 2023
Btbd11 supports cell-type-specific synaptic functionAlexei M Bygrave, Ayesha Sengupta, Ella P Jackert, et al.Brain : a Journal of Neurology|May 28, 2025
CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signaturesAlyaa M Abdel-Haleem, Ellen Casavant, Balazs Toth, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 6, 2024
CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti-tau antibody semorinemabCosme Sandoval, Julie Lee, Balazs Toth, et al.Pageof 2